How to Use LL-37 Peptide: Dosage & Protocol Guide | telos rx
Woman training with weights representing athletic recovery and immune health
← Back to blog
cathelicidin

How to Use LL-37 Peptide: Dosage, Protocol & What to Expect

By TelosRX Editorial Team Updated

LL-37 is a human cathelicidin antimicrobial peptide with emerging research in immune modulation, wound healing, and inflammation regulation. telos rx does not offer LL-37, so this guide is educational only. TelosRX can talk you through the peptides it does prescribe.

Important: LL-37 is an investigational peptide available as a compounded formulation. It is not FDA-approved, and telos rx does not offer it. Any use requires evaluation by a licensed provider. The information below is educational and does not constitute a prescription or clinical recommendation.

Step 1: Understand What LL-37 Is and How It Works

LL-37 (also written hCAP-18/LL-37) is the only human cathelicidin identified to date. It is produced naturally by neutrophils, keratinocytes, and epithelial cells and serves as a first-line defense peptide against bacteria, viruses, and fungi while also modulating the inflammatory cascade.

Research published in peer-reviewed immunology journals has characterized LL-37’s dual role: antimicrobial (direct membrane disruption of pathogens) and immunomodulatory (regulating NF-κB signaling, stimulating mast cell release, and modulating dendritic cell differentiation).

Key documented activities in preclinical and early clinical research:

  • Antimicrobial activity against gram-positive and gram-negative bacteria
  • Promotion of wound healing and re-epithelialization (human skin trials)
  • Modulation of inflammatory cytokine profiles (TNF-α, IL-6 downregulation in some contexts)
  • Antiviral activity demonstrated against respiratory syncytial virus and influenza A in vitro

Understanding the mechanism is the starting point for informed use — which begins with a provider conversation, not a self-directed protocol.

Step 2: Get a Provider Evaluation Before Starting

Because LL-37 affects immune pathways, it is not appropriate for self-directed use without medical supervision. Conditions where LL-37 may be contraindicated or require extra caution include autoimmune diseases (where immune stimulation could exacerbate symptoms), active inflammatory skin conditions, and concurrent use of immunosuppressant medications.

telos rx does not offer LL-37. If you are exploring peptides more broadly, a TelosRX provider can review your health history and goals asynchronously and discuss the options telos rx does prescribe. Approval is subject to that evaluation; it is not guaranteed. Submit your health intake at TelosRX to begin the evaluation process.

Step 3: Understand Why Grey-Market Vials Are Error-Prone

telos rx does not offer LL-37. LL-37 sold online as a "research" peptide usually comes as a freeze-dried powder. Buyers have to add a diluent themselves and then work out how much to draw for each dose, with no pharmacist checking the result. A small error in either step changes every dose that follows, and the purity and sterility of the powder are not verified for human use.

By contrast, the peptides telos rx does prescribe arrive ready to use, already prepared by a licensed US pharmacy at the dose a provider sets, so there is nothing to mix or calculate.

Any compounded peptide should be stored as its label directs, usually refrigerated, and not used if it looks cloudy or discolored, or if it is past the date on the label.

Step 4: Understand Dosage Ranges and Protocols in Research

There is no FDA-approved dosing standard for LL-37. The ranges cited below reflect investigational protocols published in peer-reviewed literature and compounding pharmacy guidance — not a clinical recommendation:

Application Area Reported Research Range Route
Immune modulation / general wellness 50–100 mcg per injection, 3–5x per week Subcutaneous
Wound healing support (investigational) 50–200 mcg, topical or subcutaneous near wound site Topical or SC
Autoimmune conditions (research only) Highly variable; no consensus protocol established Varies

Any dose, frequency, and duration would be set by a licensed provider based on an individual evaluation. Do not adjust dose without consulting that provider.

Step 5: Administer Subcutaneous Injections Safely

If your provider approves subcutaneous administration:

  1. Wash hands thoroughly with soap and water for at least 20 seconds.
  2. Prepare the injection site: rotate between the abdomen (2 inches from the navel), outer thigh, or back of the upper arm.
  3. Wipe the site with an alcohol swab and allow to dry for 10 seconds.
  4. Draw the prescribed dose from the vial using a sterile insulin syringe (typically 28 to 31 gauge).
  5. Pinch a small fold of skin, insert the needle at a 45–90 degree angle (depending on tissue depth), and inject slowly.
  6. Withdraw the needle and apply light pressure. Do not rub.
  7. Dispose of the syringe in a sharps container immediately after use.

Step 6: Monitor and Report Side Effects to Your Provider

LL-37 is generally well-tolerated in published research, but individual responses vary. Reported side effects include:

  • Mild injection site redness or swelling (common, typically resolves within hours)
  • Transient fatigue or flu-like symptoms in early cycles (less common)
  • Inflammatory flares in individuals with underlying autoimmune conditions

Contact your prescribing provider if you notice unusual swelling, rash, worsening of an existing inflammatory condition, or systemic symptoms. Do not discontinue without provider guidance.

What to Expect: Timeline of LL-37 Effects

Published research on LL-37 does not support a fixed “results by week X” timeline. Reported observations from investigational use:

  • Weeks 1–2: Injection site reactions (if any) most likely in this phase. Some users report increased energy or mild immune-activation symptoms.
  • Weeks 4–8: Wound healing studies reported measurable changes in re-epithelialization by 4–6 weeks at relevant doses.
  • Weeks 8–12+: Immune modulation effects, if present, are typically assessed at this timeframe in research protocols.

Individual results vary. LL-37 is not a supplement and its effects are not predictable from self-report data. Provider-monitored protocol with outcome reassessment is the appropriate structure.

Frequently Asked Questions

Is LL-37 peptide legal to use?

LL-37 is available as a compounded peptide through licensed compounding pharmacies with a valid prescription from a licensed provider. It is not FDA-approved. Legal use requires a prescription and is subject to state and federal compounding regulations.

How is LL-37 different from BPC-157 or TB-500?

LL-37 is a human-derived antimicrobial and immune-modulating peptide. BPC-157 is a synthetic peptide with gut and tissue repair research, and TB-500 (thymosin beta-4) is associated with actin regulation and tissue regeneration. They have distinct mechanisms and research profiles and should not be self-stacked without provider oversight.

Can I take LL-37 if I have an autoimmune condition?

LL-37 modulates immune pathways and may be contraindicated or require careful dose management in people with autoimmune conditions. This is a case where provider evaluation — not self-directed use — is essential before starting.

How long should an LL-37 cycle last?

Cycle length varies by indication. Wound healing protocols in research ran 4–6 weeks. Immune modulation protocols ranged from 8–16 weeks. Your provider will determine the appropriate cycle length and whether a rest period is indicated between cycles.

Does LL-37 need to be refrigerated?

Usually, yes. Compounded LL-37 is typically stored refrigerated at 2 to 8°C (36 to 46°F), or as its label directs. Grey-market powder vials also have to be mixed by the buyer before use, which is one reason they are error-prone. telos rx does not offer LL-37.

TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX